Biotechnology

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

New data on ATX-295 reveals a potent attack on unstable tumors, guided by an AI biomarker that could change how we select patients for treatment.

Nested Therapeutics' NST-628 reports a 38% response rate in advanced melanoma, offering new hope with a novel, brain-penetrating cancer-fighting agent.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

Vaxart's new $25M financing deal provides a crucial cash runway, but is it a savvy strategic move or a necessary step to stay in the race?

With global regulatory approvals secured, Gilead extends its tender offer for Arcellx, moving closer to acquiring a potential best-in-class CAR T therapy.

A new report reveals the Nordic life science sector isn't lacking female talent; it's failing to convert it into leadership, threatening innovation.

Early Phase 2 data shows invikafusp alfa plus TRODELVY® yields complete responses in heavily pretreated breast cancer, offering a potential new lifeline.

Biotech veteran Habib Dable, who led Acceleron to an $11.5B Merck sale, joins Tyra Biosciences' board, signaling a major push toward commercialization.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

A European consortium has won €1.3M to develop a precision therapy for chronic urticaria, offering new hope for millions with uncontrolled symptoms.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

With a successful $191M IPO, Alamar Biosciences is set to revolutionize diagnostics with its ultra-sensitive proteomics platforms.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

Biopharma veteran Glenn Gormley joins Aktis's board, bringing deep ADC expertise to guide the company's next-gen radiopharmaceutical pipeline.

San Diego's Blacksmith Medicines will present promising data on its FEN1 inhibitor, a new drug targeting a notoriously difficult class of enzymes.

A new partnership combines live biopsy analysis with agentic AI, seeking to predict immunotherapy response and solve why only 1 in 5 patients benefit.